Clinical trials: Primary CNS Lymphoma (PCNSL)
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the…
- Trial name
- NCT02315326
- Testing
- Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX)
- Where
- 7 sites in United States
- Volunteers
- 93 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Central Nervous System Lymphoma
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
This phase I trial tests the safety, side effects, and best dose of intracerebroventricularly (ICV) administered CD19-chimeric antigen receptor (CAR) T cells in treating patients with central nervous system (CNS) lymphoma.
- Trial name
- NCT05625594
- Testing
- Aspiration, Biospecimen Collection, Catheterization
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00726830
- Testing
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
CNS Lymphoma
Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients
This study is designed as an open-label, prospective, single-arm, single-center trial aimed at evaluating the efficacy and safety of MTX or Thiotepa combined with Orelabrutinib and standard chemotherapy regimens in the treatment…
- Trial name
- NCT06901999
- Testing
- Orelabrutinib, RCHOP+MTX or Thiotepa
- Volunteers
- 23 people
- Sponsor
- Ruijin Hospital
Primary Central Nervous System Lymphoma
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.
- Trial name
- NCT04070040
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing Sanbo Brain Hospital
Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
This is a open-label，multicenter, randomised, three-arm, phase II efficacy and safety study of ibrutinib in combination with MRE(methotrexate,rituximab,etoposide)-chemotherapy versus lenalidomide in combination with…
- Trial name
- NCT04129710
- Testing
- Ibrutinib, Lenalidomide, Methotrexate
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
CNS Lymphoma
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
This single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing orelabrutinib on the basis of rituximab and chemotherapy in treating patients with relapsed or refractory B-cell…
- Trial name
- NCT05926427
- Testing
- Orelabrutinib, Rituximab, Chemotherapy
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Non-hodgkin Lymphoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find…
- Trial name
- NCT05998642
- Testing
- Methotrexate, Rituximab (where available), Ibrutinib
- Where
- 8 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Canadian Cancer Trials Group
CNS Lymphoma
[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients
This will be an open, single-arm, international, multicentre, phase II imaging study to assess the predictive value of [68Ga]Ga PentixaFor PET imaging in primary and isolated secondary central nervous system lymphoma (CNSL)…
- Trial name
- NCT05222269
- Testing
- 68Ga-PTF
- Where
- 2 sites in Denmark, France
- Volunteers
- 1 people
- Sponsor
- Pentixapharm AG
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00335140
- Testing
- Rituximab, Cytarabine, Dexamethasone
- Where
- 68 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies…
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma
- Trial name
- NCT01421524
- Testing
- CC-122
- Where
- 39 sites in United States, Belgium and 3 more
- Volunteers
- 271 people
- Sponsor
- Celgene
Primary Central Nervous System Lymphoma
R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty
This is a multicenter prospective single arm phase Ib/II study, and the purpose of this study is to evaluate the safety and efficiency of R2-MTX regimen (rituximab \& lenalidomide \& methotrexate) combined with lenalidomide…
- Trial name
- REMLA (NCT04120350)
- Testing
- Methotrexate, Rituximab, Lenalidomide
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking Union Medical College Hospital
Lymphoma
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor.
- Trial name
- NCT00594815
- Testing
- Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Lymphoma
Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00416923
- Testing
- rituximab
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Non-Hodgkin's Lymphoma, CNS Lymphoma
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
Current standard treatments for lymphoma involving the central nervous system include chemotherapy or whole brain radiation therapy (WBRT).
- Trial name
- NCT01182415
- Testing
- Autologous stem cell transplant, High-dose chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS)…
- Trial name
- NCT04609046
- Testing
- Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test
- Where
- 56 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Treatment for Chronic Pain in Patients With Advanced Cancer
RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003687
- Testing
- dextromethorphan hydrobromide, morphine sulfate
- Where
- 4 sites in Canada
- Volunteers
- 87 people
- Sponsor
- NCIC Clinical Trials Group
Relapsed/Refractory Primary Central Nervous System Lymphoma
IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous…
- Trial name
- IGNITE (NCT07104032)
- Testing
- Tirabrutinib, Rituximab, Temozolomide
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 132 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Rare Disease With Poor Outcome
Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.
Primary Central Nervous System Lymphoma (PCNSL) have a specific mutational profile in comparison to systemic diffuse large cells lymphoma (DLBCLs) that can be related to the expression of immunohistochemical markers as cyclon…
- Trial name
- NCT05347511
- Volunteers
- 94 people
- Sponsor
- Central Hospital, Nancy, France